Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Radiosurg SBRT ; 8(3): 211-215, 2022.
Article in English | MEDLINE | ID: mdl-36860996

ABSTRACT

Jugulotympanic paraganglioma (JTPG), a benign slow-growing neoplasm in the skull base with a tendency to be locally invasive, poses a treatment challenge because of its proximity to nearby neurovascular structures. The authors describe 11 patents with 12 Fisch-classified JTPGs treated with GammaKnife radiosurgery (GKRS) during a 12-year period. The observed rates of subjective improvement and tumor control were 80% and 83%, respectively. Among the individuals living longer than 5 years, tumor growth developed at 77 and 180 months after radiosurgery in two patients. Treatment-related toxicity or radiation oncogenesis was not observed. GKRS seems to be a valid treatment option for all Fisch designated skull base glomus tumors. Life-long follow-up of these patients is necessary.

2.
Oral Oncol ; 102: 104518, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31862239

ABSTRACT

Metachronous mediastinal and lung metastases (MMLM), important sources of morbidity and mortality, in people with head and neck cancer (HNC) have received little attention. Between 1980 and 2004, 37 patients with treated HNC and MMLM diagnosed on follow-up imaging (with histological confirmation in 14 cases) were identified. The median interval from diagnosis of HNC to the appearance of MMLM was 14.5 months. The overall median survival was 4 months, and the 1-year crude survival rate (CSR) was 16%. A meaningful difference in the 1-year CSRs between the palliative radiation treated and untreated subjects (39% and 4%, respectively, p < 0.01) was observed. Because associated costs of health care utilization are considerable, and yet survival is limited, optimum management of MMLM-HNC with improvement of prognosis remains a challenge.


Subject(s)
Head and Neck Neoplasms/pathology , Lung Neoplasms/secondary , Mediastinal Neoplasms/secondary , Neoplasms, Second Primary/secondary , Squamous Cell Carcinoma of Head and Neck/pathology , Aged , Combined Modality Therapy , Female , Follow-Up Studies , Head and Neck Neoplasms/therapy , Humans , Lung Neoplasms/therapy , Male , Mediastinal Neoplasms/therapy , Middle Aged , Neoplasms, Second Primary/therapy , Prognosis , Retrospective Studies , Squamous Cell Carcinoma of Head and Neck/therapy
4.
Anticancer Res ; 38(12): 6797-6800, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30504392

ABSTRACT

BACKGROUND/AIM: Radiotherapy for carcinoma invasion of the sacrum (CIS) is an alternative treatment to surgery in patients with advanced, inoperable tumors or those not medically eligible for resection of the neoplasm. Herein we present an observational study of patients with imaging-confirmed CIS who were treated non-operatively with radiation. PATIENTS AND METHODS: A retrospective chart review of CIS patients treated with palliative radiotherapy (PR) during a 9-year period (2004-2013) was performed. RESULTS: Six women and 13 men with an average age of 60 years took part in this study. Most patients (84%) exhibited extrasacral metastases. Primary tumors included lung (n=6), colorectal (n=6), breast (n=3), bladder or kidney (n=2), and liver carcinoma or a tumor in an unknown primary site (n=2). The mean follow-up time was 10 months with a 2-year survival rate of 9%. The majority (71%) of symptomatic patients obtained relief from pain following PR. Half of those individuals who were non-ambulatory prior to therapy regained mobility. There were no acute ill-effects or later complications after irradiation. CONCLUSION: Despite the small cohort and poor overall survival rate, non-operative radiation treatment is a beneficial method of palliative care in patients with CIS.


Subject(s)
Cancer Pain/radiotherapy , Palliative Care/methods , Sacrum/pathology , Spinal Neoplasms/radiotherapy , Spinal Neoplasms/secondary , Aged , Aged, 80 and over , Combined Modality Therapy , Female , Humans , Male , Middle Aged , Mobility Limitation , Neoplasm Invasiveness , Radiotherapy Dosage , Radiotherapy, Adjuvant , Retrospective Studies , Sacrum/radiation effects , Spinal Neoplasms/mortality , Survival Rate
5.
Anticancer Res ; 36(6): 3049-52, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27272825

ABSTRACT

BACKGROUND: Combinations of treatment modalities for locally extensive carcinomas of the larynx constitute the standard of care. Advanced 'horseshoe' anterior commissure laryngeal cancer (HACLC) is a disease entity that has not received much attention in the literature. The aims of this study were to evaluate prolonged survival in patients after standard combined therapy for HACLC and to identify clinicopathological factors influential towards an extended outcome. PATIENTS AND METHODS: Fourteen patients (10-year survivors) with stage III or IV laryngeal cancer involving the anterior commissure and both true vocal cords were treated with total laryngectomy (and postoperative radiotherapy in 11 individuals). RESULTS: During follow-up, ranging from 123 to 256 months, locoregional recurrent disease and distant metastasis were not observed. Complications after therapy were manageable and few. The long-term survivors were particularly difficult to characterize. CONCLUSION: The optimal treatment for advanced HACLC has not been clarified; however, in this study, total laryngectomy and the indicated use of postoperative radiotherapy, were successful in achieving long-term disease-free survival. Predictive factors for longevity were not detected in this limited experience.


Subject(s)
Laryngeal Neoplasms/mortality , Adult , Aged , Combined Modality Therapy , Humans , Laryngeal Neoplasms/therapy , Laryngectomy , Middle Aged , Survival Rate , Survivors
SELECTION OF CITATIONS
SEARCH DETAIL
...